Remdesivir—Bringing Hope for COVID-19 Treatment
At the beginning of 2020, the world was swept with a wave of a new coronavirus disease, named COVID-19 by the World Health Organization (WHO 2). The causative agent of this infection is the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The data available on one of the promising thera...
Main Authors: | Naser F. Al-Tannak, Ladislav Novotny, Adel Alhunayan |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-06-01
|
Series: | Scientia Pharmaceutica |
Subjects: | |
Online Access: | https://www.mdpi.com/2218-0532/88/2/29 |
Similar Items
-
Differential cytokine responses in hospitalized COVID-19 patients limit efficacy of Remdesivir
by: Chan, Yi-Hao, et al.
Published: (2022) -
Remdesivir (GS-5734) Impedes Enterovirus Replication Through Viral RNA Synthesis Inhibition
by: Wei Ye, et al.
Published: (2020-06-01) -
Corrigendum: Remdesivir (GS-5734) Impedes Enterovirus Replication Through Viral RNA Synthesis Inhibition
by: Wei Ye, et al.
Published: (2020-11-01) -
Comparison of remdesivir and favipiravir - the anti-Covid-19 agents mimicking purine RNA constituents
by: Faiha M. Al-Ardhi, et al.
Published: (2022-03-01) -
Incidence and potential risk factors for remdesivir-associated bradycardia in hospitalized patients with COVID-19: A retrospective cohort study
by: Yazed Saleh Alsowaida, et al.
Published: (2023-02-01)